Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Production of Vascular Endothelial Growth Factor by Murine Macrophages

Identifieur interne : 003A43 ( Main/Exploration ); précédent : 003A42; suivant : 003A44

Production of Vascular Endothelial Growth Factor by Murine Macrophages

Auteurs : Ming Xiong [États-Unis] ; Genie Elson [États-Unis] ; Diana Legarda [États-Unis] ; Samuel Joseph Leibovich [États-Unis]

Source :

RBID : ISTEX:B024D4B1B3E83EED660A952AFE7C9B71312C69FC

English descriptors

Abstract

Murine thioglycolate-induced peritoneal macrophages (MPMs) and the murine RAW264.7 macrophage-like cell line (RAW cells) constitutively produce vascular endothelial growth factor (VEGF). VEGF production is increased under hypoxic conditions or after cell activation with interferon- (IFN) and endotoxin (lipopolysaccharide, LPS). In contrast, tumor necrosis factor- is produced only by IFN/LPS-activated cells. Lactate (25 mmol/L) does not increase VEGF production by these cells. However, hypoxia, lactate, and IFN/LPS-activated MPMs express angiogenic activity, whereas normoxic, nonactivated MPMs do not. Lack of angiogenic activity is not due to an antiangiogenic factor(s) in the medium of these cells. Angiogenic activity produced by hypoxia and lactate-treated MPMs is neutralized by anti-VEGF antibody, which also neutralizes most of the angiogenic activity produced by IFN/LPS-activated MPMs. The inducible nitric oxide synthase inhibitorsNg-nitro-l-arginine-methyl ester (1.5 mmol/L) and aminoguanidine (1 mmol/L) block production of angiogenic activity by MPMs and RAW cells. In RAW cells,Ng-nitro-l-arginine-methyl ester and AG block IFN/LPS-activated, but not constitutive, VEGF production, whereas in MPMs, neither constitutive nor IFN/LPS-activated VEGF synthesis is affected. Synthesis of tumor necrosis factor- is also unaffected. In contrast to normoxic, nonactivated MPMs, inducible nitric oxide synthase-inhibited, IFN/LPS-activated MPMs produce an antiangiogenic factor(s). We conclude that VEGF is a major contributor to macrophage-derived angiogenic activity, and that activation by hypoxia, lactate, or IFN/LPS switches macrophage-derived VEGF from a nonangiogenic to an angiogenic state. This switch may involve a posttranslational modification of VEGF, possibly by the process of ADP-ribosylation. ADP-ribosylation by MPM cytosolic extracts or by cholera toxin switches rVEGF165 from an angiogenic to a nonangiogenic state. In IFN/LPS-activated MPMs, the inducible nitric oxide synthase-dependent pathway also regulates the expression of an antiangiogenic factor(s) that antagonizes the bioactivity of VEGF and provides an additional regulatory pathway controlling the angiogenic phenotype of macrophages.

Url:
DOI: 10.1016/S0002-9440(10)65601-5


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>Production of Vascular Endothelial Growth Factor by Murine Macrophages</title>
<author>
<name sortKey="Xiong, Ming" sort="Xiong, Ming" uniqKey="Xiong M" first="Ming" last="Xiong">Ming Xiong</name>
</author>
<author>
<name sortKey="Elson, Genie" sort="Elson, Genie" uniqKey="Elson G" first="Genie" last="Elson">Genie Elson</name>
</author>
<author>
<name sortKey="Legarda, Diana" sort="Legarda, Diana" uniqKey="Legarda D" first="Diana" last="Legarda">Diana Legarda</name>
</author>
<author>
<name sortKey="Leibovich, Samuel Joseph" sort="Leibovich, Samuel Joseph" uniqKey="Leibovich S" first="Samuel Joseph" last="Leibovich">Samuel Joseph Leibovich</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:B024D4B1B3E83EED660A952AFE7C9B71312C69FC</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1016/S0002-9440(10)65601-5</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-SLNVXC1C-L/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002591</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002591</idno>
<idno type="wicri:Area/Istex/Curation">002591</idno>
<idno type="wicri:Area/Istex/Checkpoint">001251</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001251</idno>
<idno type="wicri:doubleKey">0002-9440:1998:Xiong M:production:of:vascular</idno>
<idno type="wicri:Area/Main/Merge">003A92</idno>
<idno type="wicri:Area/Main/Curation">003A43</idno>
<idno type="wicri:Area/Main/Exploration">003A43</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">Production of Vascular Endothelial Growth Factor by Murine Macrophages</title>
<author>
<name sortKey="Xiong, Ming" sort="Xiong, Ming" uniqKey="Xiong M" first="Ming" last="Xiong">Ming Xiong</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Department of Anatomy, Cell Biology & Injury Sciences, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Elson, Genie" sort="Elson, Genie" uniqKey="Elson G" first="Genie" last="Elson">Genie Elson</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Department of Anatomy, Cell Biology & Injury Sciences, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Legarda, Diana" sort="Legarda, Diana" uniqKey="Legarda D" first="Diana" last="Legarda">Diana Legarda</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Department of Anatomy, Cell Biology & Injury Sciences, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Leibovich, Samuel Joseph" sort="Leibovich, Samuel Joseph" uniqKey="Leibovich S" first="Samuel Joseph" last="Leibovich">Samuel Joseph Leibovich</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Department of Anatomy, Cell Biology & Injury Sciences, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark</wicri:cityArea>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">États-Unis</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">The American Journal of Pathology</title>
<title level="j" type="abbrev">AJPA</title>
<idno type="ISSN">0002-9440</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="1998">1998</date>
<biblScope unit="volume">153</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="587">587</biblScope>
<biblScope unit="page" to="598">598</biblScope>
</imprint>
<idno type="ISSN">0002-9440</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0002-9440</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Angiogenesis</term>
<term>Angiogenic</term>
<term>Angiogenic activity</term>
<term>Angiogenic effects</term>
<term>Angiogenic phenotype</term>
<term>Angiogenic responses</term>
<term>Antiangiogenic</term>
<term>Antiangiogenic activity</term>
<term>Antiangiogenic factor</term>
<term>Assay</term>
<term>August</term>
<term>Bioactivity</term>
<term>Biol</term>
<term>Biol chem</term>
<term>Chem</term>
<term>Cholera</term>
<term>Cholera toxin</term>
<term>Constitutive</term>
<term>Constitutive production</term>
<term>Cornea</term>
<term>Cytosolic</term>
<term>Eluate</term>
<term>Exon</term>
<term>Growth factor</term>
<term>Human monocytes</term>
<term>Hypoxia</term>
<term>Hypoxic</term>
<term>Hypoxic conditions</term>
<term>Inhibitor</term>
<term>Inos</term>
<term>Inos inhibitors</term>
<term>Inos pathway</term>
<term>Isoforms</term>
<term>Lactate</term>
<term>Leibovich</term>
<term>Macrophage</term>
<term>Macrophage cytosolic</term>
<term>Minigene</term>
<term>Monocyte</term>
<term>Mpms</term>
<term>Mrna</term>
<term>Murine</term>
<term>Nitric</term>
<term>Nitric oxide</term>
<term>Nitrite</term>
<term>Nitrite production</term>
<term>Nonactivated</term>
<term>Nonactivated mpms</term>
<term>Nonangiogenic</term>
<term>Nonstimulated</term>
<term>Normoxic</term>
<term>Normoxic conditions</term>
<term>Oxygen tension</term>
<term>Pathway</term>
<term>Pertussis</term>
<term>Pertussis toxin</term>
<term>Polverini</term>
<term>Posttranslational</term>
<term>Posttranslational modification</term>
<term>Primer</term>
<term>Proc natl acad</term>
<term>Reaction mixture</term>
<term>Room temperature</term>
<term>Rvegf</term>
<term>Sodium lactate</term>
<term>Toxin</term>
<term>Transferase</term>
<term>Various conditions</term>
<term>Vegf</term>
<term>Vegf mrna</term>
<term>Vegf mrna isoforms</term>
<term>Vegf mrna levels</term>
<term>Vegf production</term>
<term>Xiong</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Murine thioglycolate-induced peritoneal macrophages (MPMs) and the murine RAW264.7 macrophage-like cell line (RAW cells) constitutively produce vascular endothelial growth factor (VEGF). VEGF production is increased under hypoxic conditions or after cell activation with interferon- (IFN) and endotoxin (lipopolysaccharide, LPS). In contrast, tumor necrosis factor- is produced only by IFN/LPS-activated cells. Lactate (25 mmol/L) does not increase VEGF production by these cells. However, hypoxia, lactate, and IFN/LPS-activated MPMs express angiogenic activity, whereas normoxic, nonactivated MPMs do not. Lack of angiogenic activity is not due to an antiangiogenic factor(s) in the medium of these cells. Angiogenic activity produced by hypoxia and lactate-treated MPMs is neutralized by anti-VEGF antibody, which also neutralizes most of the angiogenic activity produced by IFN/LPS-activated MPMs. The inducible nitric oxide synthase inhibitorsNg-nitro-l-arginine-methyl ester (1.5 mmol/L) and aminoguanidine (1 mmol/L) block production of angiogenic activity by MPMs and RAW cells. In RAW cells,Ng-nitro-l-arginine-methyl ester and AG block IFN/LPS-activated, but not constitutive, VEGF production, whereas in MPMs, neither constitutive nor IFN/LPS-activated VEGF synthesis is affected. Synthesis of tumor necrosis factor- is also unaffected. In contrast to normoxic, nonactivated MPMs, inducible nitric oxide synthase-inhibited, IFN/LPS-activated MPMs produce an antiangiogenic factor(s). We conclude that VEGF is a major contributor to macrophage-derived angiogenic activity, and that activation by hypoxia, lactate, or IFN/LPS switches macrophage-derived VEGF from a nonangiogenic to an angiogenic state. This switch may involve a posttranslational modification of VEGF, possibly by the process of ADP-ribosylation. ADP-ribosylation by MPM cytosolic extracts or by cholera toxin switches rVEGF165 from an angiogenic to a nonangiogenic state. In IFN/LPS-activated MPMs, the inducible nitric oxide synthase-dependent pathway also regulates the expression of an antiangiogenic factor(s) that antagonizes the bioactivity of VEGF and provides an additional regulatory pathway controlling the angiogenic phenotype of macrophages.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>New Jersey</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="New Jersey">
<name sortKey="Xiong, Ming" sort="Xiong, Ming" uniqKey="Xiong M" first="Ming" last="Xiong">Ming Xiong</name>
</region>
<name sortKey="Elson, Genie" sort="Elson, Genie" uniqKey="Elson G" first="Genie" last="Elson">Genie Elson</name>
<name sortKey="Legarda, Diana" sort="Legarda, Diana" uniqKey="Legarda D" first="Diana" last="Legarda">Diana Legarda</name>
<name sortKey="Leibovich, Samuel Joseph" sort="Leibovich, Samuel Joseph" uniqKey="Leibovich S" first="Samuel Joseph" last="Leibovich">Samuel Joseph Leibovich</name>
<name sortKey="Leibovich, Samuel Joseph" sort="Leibovich, Samuel Joseph" uniqKey="Leibovich S" first="Samuel Joseph" last="Leibovich">Samuel Joseph Leibovich</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A43 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A43 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:B024D4B1B3E83EED660A952AFE7C9B71312C69FC
   |texte=   Production of Vascular Endothelial Growth Factor by Murine Macrophages
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021